BioPharma Dive October 17, 2024
The French drugmaker will invest 300 million euros into a new entity that will develop lead isotope-based therapies for cancer.
Dive Brief:
- Sanofi will invest 300 million euros, or about $325 million, for a roughly 16% stake in a new joint venture set up to develop radiopharmaceutical drugs for rare cancers.
- The newly created entity will operate under the banner of Orano Med, a radiopharmaceutical developer and Sanofi’s partner in the joint venture. Orano Med, which is a subsidiary of the Orano Group, specializes in versions of the targeted cancer therapy that use a radioisotope known as lead-212.
- Last month, Sanofi licensed an experimental radiopharma drug for neuroendocrine tumors, paying Orano Med and U.S.-based RadioMedix 100 million euros upfront...
Today's Sponsors
Today's Sponsor